Sean D. Sullivan, PhD

home / authors / sean-d-sullivan-phd

Articles

August 16th 2022

Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes

Michał Pochopień, MSc David Z. I. Cherney, MD, PhD Aleksandra Drzewiecka, MSc Kerstin Folkerts, MSc Pierre Levy, PhD Aurélie Millier, PhD Stephen Morris, PhD Monika Palarczyk, MSc Prabir Roy-Chaudhury, MD, PhD Sean D. Sullivan, PhD Paul Mernagh, MCom

December 8th 2021

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

Michał Pochopień, MSc David Z. I. Cherney, MD, PhD Kerstin Folkerts, MSc Pierre Levy, PhD Aurélie Millier, PhD Stephen Morris, PhD Prabir Roy-Chaudhury, MD, PhD Sean D. Sullivan, PhD Paul Mernagh, MCom

December 8th 2021

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

March 27th 2017

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Kai Yeung, PharmD, PhD Anirban Basu, PhD Zachary A. Marcum, PharmD, PhD John B. Watkins, PharmD, MPH, BCPS Sean D. Sullivan, PhD

A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.

September 15th 2015

Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects

Louis P. Garrison, Jr, PhD Josh J. Carlson, PhD Preeti S. Bajaj, PhD Adrian Towse, MA, MPhil Peter J. Neumann, ScD Sean D. Sullivan, PhD Kimberly Westrich, MA Robert W. Dubois, MD, PhD

Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.

October 11th 2011

Increasing Pharmaceutical Copayments: Impact on Asthma Medication Utilization and Outcomes

Jonathan D. Campbell, PhD Felicia Allen-Ramey, PhD Shiva G. Sajjan, PhD Eric M. Maiese, PhD Sean D. Sullivan, PhD

Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.

September 21st 2010

Colony-Stimulating Factor Prescribing Patterns in Patients Receiving Chemotherapy for Cancer

Scott D. Ramsey, MD, PhD Jeannine S. McCune, PharmD David K. Blough, PhD Cara L. McDermott, BA Lauren Clarke, MS Jennifer L. Malin, MD, PhD Sean D. Sullivan, PhD

We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.

July 1st 2007

Quality of Clinical and Economic Evidence in Dossier Formulary Submissions

Fernando Colmenero, MD Sean D. Sullivan, PhD Jennifer A. Palmer, MS Carmen A. Brauer, MD Kathleen Bungay, PharmD John Watkins, RPh, MPH Peter J. Neumann, ScD

April 1st 2006

Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests

Scott D. Ramsey, MD, PhD David L. Veenstra, PharmD, PhD Louis P. Garrison, Jr, PhD Rick Carlson, JD Paul Billings, MD, PhD Josh Carlson, MS Sean D. Sullivan, PhD

August 1st 2004

Consensus Guidelines for Specialty Pharmaceuticals: A Best-Practice Approach for Cost-Effective Management

Sean D. Sullivan, PhD

January 1st 2000

Optimizing Quality of Care and Cost Effectiveness in Treating Allergic Rhinitis in a Managed Care Setting

David B. Nash, MD, MBA, FACP Sean D. Sullivan, PhD John Mackowiak, PhD